$HLYK company has a number of inherent advantages, which is why it’s worth considering in the first place. The EMR problem is so widespread and so costly – in time, energy, and money, and for most all of us, most all of the time – that’s it’s almost hard to see. Like fish may have a hard time seeing water. We swim in inefficient dysfunction when it comes to our management of the mandate towards “electronifying” our medical records system.
But the company is guided by a proven executer: Dr. Michael Dent has had huge success, taking NeoGenomics – a Nasdaq listed company – to billion-dollar market-cap status, driving the stock up as much as 25,900% before stepping aside with his exit. NEO has continued to thrive, with a current market cap of $2 billion today.
He has brought in some of his longstanding top teammates for the HealthLynked project, which should inspire confidence for shareholders. In that vein, the company’s recent performance should inspire accelerating excitement: For the three months ended June 30, 2019, the company reported tremendous year-over-year gains, including a 113% increase in revenue in Q2’19 compared to Q2’18, a 13% jump in patient appointments (from 4,010 in Q2’18 to 4,533 in Q2’19), and a 426% jump in “Time of Service” collections (from $152,174 in Q2’18 to $801,067 in Q2’19). The company’s sequential quarterly growth was also powerful, with a 160% increase in revenue to $1,208,390 in Q2’19 compared to $464,990 in Q1’19, a 22% jump in patient appts (from 3,712 in Q1’19 to 4,533 in Q2’19), and a 526% jump in “Time of Service” (from $127,809 in Q1’19 to $801,067 in Q2’19). HealthLynked (HLYK) Looks Ahead at Exciting Times https://bullishguru.com/healthlynked-hlyk-loo...ing-times/
But the company is guided by a proven executer: Dr. Michael Dent has had huge success, taking NeoGenomics – a Nasdaq listed company – to billion-dollar market-cap status, driving the stock up as much as 25,900% before stepping aside with his exit. NEO has continued to thrive, with a current market cap of $2 billion today.
He has brought in some of his longstanding top teammates for the HealthLynked project, which should inspire confidence for shareholders. In that vein, the company’s recent performance should inspire accelerating excitement: For the three months ended June 30, 2019, the company reported tremendous year-over-year gains, including a 113% increase in revenue in Q2’19 compared to Q2’18, a 13% jump in patient appointments (from 4,010 in Q2’18 to 4,533 in Q2’19), and a 426% jump in “Time of Service” collections (from $152,174 in Q2’18 to $801,067 in Q2’19). The company’s sequential quarterly growth was also powerful, with a 160% increase in revenue to $1,208,390 in Q2’19 compared to $464,990 in Q1’19, a 22% jump in patient appts (from 3,712 in Q1’19 to 4,533 in Q2’19), and a 526% jump in “Time of Service” (from $127,809 in Q1’19 to $801,067 in Q2’19). HealthLynked (HLYK) Looks Ahead at Exciting Times https://bullishguru.com/healthlynked-hlyk-loo...ing-times/
